Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis
Authors:
- 26 August 2005
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (5) , 463-470
Abstract
Summary: Background : Local treatment with foams in patients suffering from ulcerative proctitis or proctosigmoiditis is considered a rational treatment option.Aims : To investigate colonic spread, safety, tolerability and acceptance of a newly developed budesonide foam formulation.Methods : Twelve patients (four females, eight males) with acute proctosigmoiditis or left‐sided ulcerative colitis were rectally administered a single dose of [99Tcm]‐labelled budesonide foam (Budenofalk; Dr Falk Pharma GmbH, Freiburg, Germany) containing 2 mg budesonide in 20 mL foam after diagnostic colonoscopy. Thereafter, the colonic spread was assessed by means of γ‐scintigraphy for 6 h. Serum samples were taken simultaneously.Results : Budesonide foam spread with a maximum between 11 and 40 cm, thus reaching the sigmoid colon in all patients. In some patients, the foam even extended into the distal third and the middle of the descending colon with maximum radioactivity at 4 h. Systemic budesonide absorption was rapid and pharmacokinetic data were comparable with published data on marketed budesonide enemas, with mean serum Cmax and AUC0‐8h values of 0.8 ± 0.5 ng/mL and 3.7 ± 1.9 ng h/mL, respectively. The new formulation was well accepted by all patients, who could retain the foam for at least 4 h.Conclusions : In the majority of patients, budesonide foam effectively spread up to the left‐sided colon and thus qualifies for the local treatment of proctosigmoiditis.Keywords
This publication has 29 references indexed in Scilit:
- Management of inflammatory bowel disease2004
- Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early– and Late–Stage Primary Biliary CirrhosisHepatology, 2003
- Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitisAlimentary Pharmacology & Therapeutics, 1994
- Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitisEuropean Journal of Gastroenterology & Hepatology, 1994
- Better quality of therapy with 5-ASA colonic foam in active ulcerative colitisDigestive Diseases and Sciences, 1993
- Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitisDigestive Diseases and Sciences, 1992
- Lack of Pharmacokinetic Interactions Between Moxonidine and DigoxinClinical Pharmacokinetics, 1992
- Budesonide Enema in Distal Ulcerative Colitis: a Randomized Dose-Response Trial with Prednisolone Enema as Positive ControlScandinavian Journal of Gastroenterology, 1991
- A Controlled Randomized Trial of Budesonide versus Prednisolone Retention Enemas in Active Distal Ulcerative ColitisScandinavian Journal of Gastroenterology, 1987
- Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas.BMJ, 1985